PreveCeutical Medical Inc. Stock

Equities

PREV

CA74141E1043

Pharmaceuticals

Market Closed - Canadian Securities Exchange 03:25:04 2024-05-10 pm EDT 5-day change 1st Jan Change
0.025 CAD 0.00% Intraday chart for PreveCeutical Medical Inc. +25.00% 0.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2021 - Sales 2022 - Capitalization 13.38M 9.78M
Net income 2021 -1M -731K Net income 2022 -1M -731K EV / Sales 2021 -
Net Debt 2021 2.91M 2.13M Net Debt 2022 3.29M 2.4M EV / Sales 2022 -
P/E ratio 2021
-7.36 x
P/E ratio 2022
-8.81 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 75.91%
More Fundamentals * Assessed data
Dynamic Chart
PreveCeutical Medical Inc. announced that it expects to receive CAD 0.25 million in funding CI
PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program CI
PreveCeutical Medical Prepares For Proof of Concept Preclinical Study For Diabetes, Obesity Dual Gene Therapy Program MT
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
PreveCeutical & Endosane Announce Update on Intranasal CBD Application MT
PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD Application CI
PreveCeutical Medical Inc. Showcases Dynamic Evolution in AI Strategy CI
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
PrevCeutical Medical Provides Update MT
PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and Australia CI
PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof CI
Preveceutical Medical Inc. Furthering the Progress of Its Patent Family Directed to Sol-Gel CI
PreveCeutical Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
PreveCeutical Medical Inc. Auditor Raises 'Going Concern' Doubt CI
PreveCeutical Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
1 week+25.00%
3 months+25.00%
6 months-16.67%
More quotes
1 week
0.02
Extreme 0.015
0.03
1 month
0.02
Extreme 0.015
0.03
Current year
0.02
Extreme 0.015
0.03
1 year
0.02
Extreme 0.015
0.03
3 years
0.02
Extreme 0.015
0.04
5 years
0.01
Extreme 0.01
0.10
10 years
0.01
Extreme 0.01
0.20
More quotes
Managers TitleAgeSince
Founder - 14-12-14
Chief Executive Officer - 14-12-14
Founder - 14-12-14
Members of the board TitleAgeSince
Director/Board Member 64 23-02-16
Founder 73 14-12-14
Chief Executive Officer - 14-12-14
More insiders
Date Price Change Volume
24-05-10 0.025 0.00% 18,588
24-05-08 0.025 0.00% 95,500
24-05-07 0.025 +66.67% 1,201,000
24-05-06 0.015 -25.00% 45,000

Delayed Quote Canadian Securities Exchange, May 10, 2024 at 03:25 pm EDT

More quotes
PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Company’s subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW